Roche in Cancer Care

The Roche Group is the world's leading provider of cancer care products. Our anti-cancer medicines are saving lives and significantly advancing the way some cancers are treated. The Roche portfolio currently includes five innovative cancer products proven to provide survival benefit in a number of different tumor types: Avastin® (bevacizumab), Herceptin® (trastuzumab), Xeloda® (capecitabine), MabThera® (rituximab) and Tarceva® (erlotinib).

In addition, Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future. With a broad portfolio of tumour markers as well as a range of molecular oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics.

Attached media for this topic

About oncology
About Roche in oncologyPDF
Roche Oncology R&DPDF
Personalized Healthcare in OncologyPDF
Epidemiology of cancerPDF
Specific indications
Breast cancer PDF
Stomach cancer PDF
Chronic Lymphocytic LeukemiaPDF
Colorectal cancer PDF
Non-Hodgkin's Lymphoma PDF
Non Small Cell Lung cancer PDF
HER2-positive cancerPDF
Skin cancer (Melanoma) PDF
Ovarian cancerPDF
Advanced Basal Cell CarcinomaPDF
Cervical cancer PDF
Info graphic
Cervical cancerPDF
Lung cancerPDF
Stages of Breast cancerPDF
HER2-Breast cancerPDF
Colorectal cancerPDF
Non Hodgkins LymphomaPDF
Chronic lymphocytic leukemiaPDF
Advanced Basal Cell CarcinomaPDF
Avastin ProductionZIP